RPHM Reneo Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RPHM

Price (delayed)

$1.74

Market cap

$58.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.52

Enterprise value

$31.49M

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of ...

Highlights
RPHM's debt is down by 33% year-on-year and by 14% since the previous quarter
The quick ratio has plunged by 60% YoY and by 39% from the previous quarter
Reneo Pharmaceuticals's net income has decreased by 49% YoY and by 15% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://reneopharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of RPHM
Market
Shares outstanding
33.42M
Market cap
$58.15M
Enterprise value
$31.49M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.65
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$77.39M
EBITDA
-$76.86M
Free cash flow
-$63.9M
Per share
EPS
-$2.52
Free cash flow per share
-$2.08
Book value per share
$2.66
Revenue per share
$0
TBVPS
$3.5
Balance sheet
Total assets
$107.44M
Total liabilities
$18.83M
Debt
$973,000
Equity
$88.61M
Working capital
$88.45M
Liquidity
Debt to equity
0.01
Current ratio
5.87
Quick ratio
5.66
Net debt/EBITDA
0.35
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-63.9%
Return on equity
-73.2%
Return on invested capital
-87.3%
Return on capital employed
-86.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RPHM stock price

How has the Reneo Pharmaceuticals stock price performed over time
Intraday
0.58%
1 week
4.19%
1 month
1.75%
1 year
-82.37%
YTD
8.75%
QTD
4.82%

Financial performance

How have Reneo Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$83.05M
Net income
-$77.39M
Gross margin
N/A
Net margin
N/A
Reneo Pharmaceuticals's operating income has plunged by 54% YoY and by 14% from the previous quarter
Reneo Pharmaceuticals's net income has decreased by 49% YoY and by 15% QoQ

Growth

What is Reneo Pharmaceuticals's growth rate over time

Valuation

What is Reneo Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
RPHM's EPS is down by 19% year-on-year and by 6% since the previous quarter
The P/B is 59% less than the last 4 quarters average of 1.6
The equity is down by 23% since the previous quarter and by 11% year-on-year

Efficiency

How efficient is Reneo Pharmaceuticals business performance
RPHM's ROE has dropped by 66% year-on-year and by 18% since the previous quarter
RPHM's ROA has dropped by 56% year-on-year and by 15% since the previous quarter
Reneo Pharmaceuticals's return on invested capital has increased by 33% YoY but it has decreased by 21% QoQ

Dividends

What is RPHM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RPHM.

Financial health

How did Reneo Pharmaceuticals financials performed over time
The total liabilities has soared by 129% YoY and by 22% QoQ
Reneo Pharmaceuticals's current ratio has plunged by 61% YoY and by 38% from the previous quarter
RPHM's debt is 99% smaller than its equity
RPHM's debt is down by 33% year-on-year and by 14% since the previous quarter
The equity is down by 23% since the previous quarter and by 11% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.